Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7371727 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
US7704947 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
US8080526 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
US7745409 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
US7304036 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8110553 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
US8933030 | ALLERGAN | Treatments for gastrointestinal disorders |
Feb, 2031
(8 years from now) | |
US10702576 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(8 years from now) | |
US10675325 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(8 years from now) | |
US8748573 | ALLERGAN | Formulations comprising linaclotide |
Oct, 2031
(8 years from now) | |
US8802628 | ALLERGAN | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(8 years from now) | |
US9708371 | ALLERGAN | Treatments for gastrointestinal disorders |
Aug, 2033
(10 years from now) |
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.
Dosage: CAPSULE;ORAL
83
United States
22
Japan
12
Korea, Republic of
11
European Union
10
Mexico
10
China
8
Spain
8
Canada
7
Australia
7
Denmark
5
Slovenia
5
Portugal
4
Brazil
4
Poland
4
Hungary
4
South Africa
4
Russia
4
Singapore
4
New Zealand
3
Hong Kong
3
Lithuania
3
Cyprus
3
Norway
2
Austria
2
RS
2
Luxembourg
2
Ukraine
2
Germany
2
Israel
2
Argentina
2
Peru
2
EA
2
Croatia
1
Chile
1
Uruguay
1
Netherlands
1
Colombia
1
Georgia
1
Turkey
1
Philippines
1
Taiwan, Province of China
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic